Related Experiment Video

Updated: Jul 9, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F)

V Guerini1, V Barbui, O Spinelli

  • 1Hematology Unit, Ospedali Riuniti, Bergamo, Italy.

Leukemia
|December 15, 2007
PubMed

Insights

ITF2357, a novel histone deacetylase inhibitor (HDACi), effectively inhibits proliferation of cells with the JAK2(V617F) mutation found in polycythemia vera and essential thrombocythemia. This targeted action occurs at low concentrations, suggesting a specific therapeutic approach.

Area of Science:

  • Oncology
  • Hematology
  • Molecular Biology

Background:

  • The JAK2(V617F) mutation is a key driver in myeloproliferative neoplasms like polycythemia vera (PV) and essential thrombocythemia (ET).
  • Histone deacetylase inhibitors (HDACi) are being explored for their antitumor potential.
  • ITF2357 is a novel HDACi with demonstrated antitumor activity.

Purpose of the Study:

  • To investigate the efficacy of ITF2357 against cells harboring the JAK2(V617F) mutation.
  • To determine the specific molecular mechanisms by which ITF2357 affects JAK2(V617F)-mutated cells.

Main Methods:

  • Cell culture of JAK2(V617F) mutated cells (PV, ET, HEL cell line) and control cell lines.
  • Assessment of clonogenic activity and cell proliferation inhibition via ITF2357 treatment.
  • Western blotting to analyze protein levels of JAK2, phosphorylated JAK2, STAT proteins, and phosphorylated STAT proteins.
  • Real-time PCR to evaluate gene expression changes, including JAK2(V617F) mRNA and PRV-1 gene expression.

Main Results:

  • ITF2357 significantly inhibited clonogenic activity of JAK2(V617F) mutated cells at low concentrations (IC50 0.001-0.01 microM).
  • ITF2357 treatment led to the downregulation of total and phosphorylated JAK2(V617F), pSTAT5, and pSTAT3 in HEL cells.
  • While JAK2(V617F) mRNA levels remained unchanged, the expression of the JAK2 target gene PRV-1 was rapidly downregulated in PV patient granulocytes upon ITF2357 exposure.

Conclusions:

  • ITF2357 demonstrates potent and specific inhibitory activity against JAK2(V617F)-mutated cells.
  • The drug targets the JAK2(V617F) protein and its downstream signaling pathways (STAT proteins).
  • ITF2357 represents a promising therapeutic agent for myeloproliferative neoplasms driven by the JAK2(V617F) mutation.

More Related Videos

Assays for Validating Histone Acetyltransferase Inhibitors09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...